Clinical Trials | March 07, 2026
Roche’s Gazyva shows breakthrough results in Lupus phase III trial
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
The company announced positive topline data from the Phase II ZUPREME-1 trial
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
ShunzymeX leverages a proprietary protease to streamline purification
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
Merck emphasized the broader significance of the findings
This study evaluated a difficult-to-treat Crohn's disease patient population
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Subscribe To Our Newsletter & Stay Updated
